Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | RET |
| Variant | wild-type |
| Impact List | none |
| Protein Effect | no effect |
| Gene Variant Descriptions | Wild-type RET indicates that no mutation has been detected within the RET gene. |
| Associated Drug Resistance | |
| Category Variants Paths |
RET wild-type |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET wild-type | lung small cell carcinoma | sensitive | Vandetanib | Preclinical | Actionable | In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427). | 25122427 |
| RET wild-type | lung small cell carcinoma | sensitive | Ponatinib | Preclinical | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427). | 25122427 |